Compare MNMD & GES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNMD | GES |
|---|---|---|
| Founded | 2019 | 1981 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.2M | 872.4M |
| IPO Year | N/A | 1996 |
| Metric | MNMD | GES |
|---|---|---|
| Price | $12.64 | $16.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $25.78 | $19.88 |
| AVG Volume (30 Days) | ★ 1.6M | 558.5K |
| Earning Date | 11-06-2025 | 11-25-2025 |
| Dividend Yield | N/A | ★ 5.32% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $3,144,417,000.00 |
| Revenue This Year | N/A | $8.97 |
| Revenue Next Year | N/A | $4.07 |
| P/E Ratio | ★ N/A | $15.79 |
| Revenue Growth | N/A | ★ 6.44 |
| 52 Week Low | $4.70 | $8.48 |
| 52 Week High | $14.43 | $17.15 |
| Indicator | MNMD | GES |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 51.88 |
| Support Level | $11.80 | $16.92 |
| Resistance Level | $13.45 | $17.15 |
| Average True Range (ATR) | 0.73 | 0.11 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 73.54 | 46.77 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.